55
Participants
Start Date
June 2, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2028
IBI343
"Subjects in the phase 1b stage will receive IBI343 3/4.5/6mg/kg intravenous infusion (IV) D1 Q3W in 3-week cycles.~Subjects in the phase 2 stage will receive IBI343 RP2D intravenous IV D1 Q3W in 3-week cycles."
Sintilimab
Subjects will receive sintilimab 200mg IV D1 Q3W in 3-week cycles.
Oxaliplatin
Subjects will receive oxaliplatin 130mg/m2 IV D1 Q3W in 3-week cycles.
S-1
Subjects will receive S-1 40-60mg BID PO D1-14 Q3W in 3-week cycles.
RECRUITING
Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Jiao Tong University School of Medicine
OTHER
Ruijin Hospital
OTHER